Literature DB >> 7821306

Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension.

K Pyörälä1, G De Backer, I Graham, P Poole-Wilson, D Wood.   

Abstract

Entities:  

Mesh:

Year:  1994        PMID: 7821306     DOI: 10.1093/oxfordjournals.eurheartj.a060388

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  89 in total

1.  Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.

Authors:  D M Pickin; C J McCabe; L E Ramsay; N Payne; I U Haq; W W Yeo; P R Jackson
Journal:  Heart       Date:  1999-09       Impact factor: 5.994

Review 2.  What is the optimal age for starting lipid lowering treatment? A mathematical model.

Authors:  S Ulrich; A D Hingorani; J Martin; P Vallance
Journal:  BMJ       Date:  2000-04-22

3.  Cholesterol screening and management guidelines. Having several guidelines is confusing.

Authors:  S Bulusu
Journal:  BMJ       Date:  1999-04-24

Review 4.  Primary and secondary prevention of heart disease: can we curb the global epidemic?

Authors:  S C Smith
Journal:  Trans Am Clin Climatol Assoc       Date:  2001

Review 5.  Impact of dyslipidaemia. Lessons from clinical trials.

Authors:  W V Brown
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 6.  Resource utilisation in the management of dyslipidaemia.

Authors:  T D Szucs
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

7.  Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men.

Authors:  I U Haq; L E Ramsay; W W Yeo; P R Jackson; E J Wallis
Journal:  Heart       Date:  1999-01       Impact factor: 5.994

Review 8.  [Evaluation of cardiovascular risk. What table to use?].

Authors:  A Maiques Galán
Journal:  Aten Primaria       Date:  2003-12       Impact factor: 1.137

Review 9.  Risk factor thresholds: their existence under scrutiny.

Authors:  M R Law; N J Wald
Journal:  BMJ       Date:  2002-06-29

10.  Comparison of current guidelines for primary prevention of coronary heart disease: risk assessment and lipid-lowering therapy.

Authors:  Uli C Broedl; Hans-Christian Geiss; Klaus G Parhofer
Journal:  J Gen Intern Med       Date:  2003-03       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.